WO2009004146A3 - Nouveaux dérives analogues de l'herbimycine a, compositions les contenant et utilisation - Google Patents

Nouveaux dérives analogues de l'herbimycine a, compositions les contenant et utilisation Download PDF

Info

Publication number
WO2009004146A3
WO2009004146A3 PCT/FR2008/000709 FR2008000709W WO2009004146A3 WO 2009004146 A3 WO2009004146 A3 WO 2009004146A3 FR 2008000709 W FR2008000709 W FR 2008000709W WO 2009004146 A3 WO2009004146 A3 WO 2009004146A3
Authority
WO
WIPO (PCT)
Prior art keywords
herbimycin
novel
compositions containing
ring
containing same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2008/000709
Other languages
English (en)
Other versions
WO2009004146A2 (fr
Inventor
Veronique Bellosta
Antony Bigot
Sophie Canova
Janine Cossy
Patrick Mailliet
Serge Mignani
Herve Minoux
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Aventis France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis France filed Critical Sanofi Aventis France
Publication of WO2009004146A2 publication Critical patent/WO2009004146A2/fr
Publication of WO2009004146A3 publication Critical patent/WO2009004146A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Produits de formule (I), avec A représente l'un des trois cycles suivants: cycle a, cycle b, cycle c et W représente hydrogène ou -(C1-C4)alkyle, -(C1 -C4)alkényle, -CO-(C1 -C3)alkyle, - CO-(C1-C3)alkényle, -CO-NH-(C1 -C2)alkyle, -CO-NH-(C1 -C2)alkényle ou -CO-NH2; le carbone C15 ayant la configuration stéréochimique R ou S, et la double liaison entre les carbones C4 et C5 ayant une géométrie E ou Z, étant entendu que lorsque A représente le cycle b et le carbone C15 a la configuration stéréochimique R alors W ne représente pas hydrogène ou méthyle, ces produits étant sous toutes les formes isomères et les sels, à titre de médicaments.
PCT/FR2008/000709 2007-05-24 2008-05-23 Nouveaux dérives analogues de l'herbimycine a, compositions les contenant et utilisation Ceased WO2009004146A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0703673 2007-05-24
FR0703673A FR2916443B1 (fr) 2007-05-24 2007-05-24 Nouveaux derives analogues de l'herbimycine a, compositions les contenant et utilisation.

Publications (2)

Publication Number Publication Date
WO2009004146A2 WO2009004146A2 (fr) 2009-01-08
WO2009004146A3 true WO2009004146A3 (fr) 2009-08-20

Family

ID=38871683

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/000709 Ceased WO2009004146A2 (fr) 2007-05-24 2008-05-23 Nouveaux dérives analogues de l'herbimycine a, compositions les contenant et utilisation

Country Status (3)

Country Link
AR (1) AR066703A1 (fr)
FR (1) FR2916443B1 (fr)
WO (1) WO2009004146A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR077405A1 (es) 2009-07-10 2011-08-24 Sanofi Aventis Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer
FR2949467B1 (fr) 2009-09-03 2011-11-25 Sanofi Aventis Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation
SI3030549T1 (sl) 2013-09-12 2019-08-30 Janssen Biopharma, Inc. Spojine piridazinona in njihove uporabe
CN117700313B (zh) * 2023-12-14 2025-02-14 怒江绿色香料产业研究院 一种羟基十四烯醛及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001049A1 (fr) * 2005-06-29 2007-01-04 Kyowa Hakko Kogyo Co., Ltd. Dérivé de l'ansamycine benzénoïde

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007001049A1 (fr) * 2005-06-29 2007-01-04 Kyowa Hakko Kogyo Co., Ltd. Dérivé de l'ansamycine benzénoïde

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Section Ch Week 200721, Derwent World Patents Index; Class B02, AN 2007-207373, XP002465719 *
SCHNUR R C ET AL: "Inhibition of the oncogene product p185erbB-2 in vitro and in vivo by geldanamycin and dihydrogeldanamycin derivatives.", 15 September 1995, JOURNAL OF MEDICINAL CHEMISTRY 15 SEP 1995, VOL. 38, NR. 19, PAGE(S) 3806 - 3812, ISSN: 0022-2623, XP002465718 *
STEAD P ET AL: "Discovery of novel ansamycins possessing potent inhibitory activity in a Cell-based Oncostatin M signalling assay", JOURNAL OF ANTIBIOTICS, JAPAN ANTIBIOTICS RESEARCH ASSOCIATION, TOKYO, JP, vol. 53, no. 7, July 2000 (2000-07-01), pages 657 - 663, XP002988238, ISSN: 0021-8820 *

Also Published As

Publication number Publication date
FR2916443A1 (fr) 2008-11-28
FR2916443B1 (fr) 2012-08-03
AR066703A1 (es) 2009-09-09
WO2009004146A2 (fr) 2009-01-08

Similar Documents

Publication Publication Date Title
MX2009000884A (es) Derivados de piridizinona.
TN2013000253A1 (en) Bicyclo[3.2.1]octyl amide derivatives and uses of same
GEP20227397B (en) Inhibitors of influenza viruses replication
PH12016502539A1 (en) Indane and indoline derivatives and the use thereof as soluble guanylate cyclase activators
TW200628161A (en) Novel betulin derivatives, preparation thereof and use thereof
TW200801000A (en) Spiroindolinone derivatives
TW200728307A (en) Novel spirochromanone derivatives
CA2725933A1 (fr) Combinaisons de medicaments comprenant un inhibiteur de dgat et un agoniste de ppar
MX2009013804A (es) Inhibidores novedosos de transcriptasa inversa de vih.
MX2009004746A (es) Derivados de 1,2,4-triazol como inhibidores del receptor sigma.
PT2310356E (pt) Derivados de adamantildiamida e a sua utilização
TN2011000258A1 (en) Pharmaceutical composition of a potent hcv inhibitor for oral administration
MX2011008176A (es) Derivados de 3,3'-espiroindolinona como agentes anticancerigenos.
MY178894A (en) Therapeutic compositions containing macitentan
WO2012101011A3 (fr) Nouveaux dérivés d'arylbenzocycloalkylamides
MX353209B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
MX2010009645A (es) Derivados novedosos de aminometil benceno.
MX2011012199A (es) Derivados de benzoxazolona como inhibidores de la sintasa de aldosterona.
MY143581A (en) Carboxamide derivatives as muscarinic receptor antagonists
TN2012000105A1 (en) Spirolactam derivatives and uses of same
WO2012128582A3 (fr) Composé capable d'inhiber la 11-bêta-hydroxystéroïde déshydrogénase de type 1 humaine et composition pharmaceutique en contenant
UA103329C2 (ru) Соли соединений-ингибиторов вич
WO2009004146A3 (fr) Nouveaux dérives analogues de l'herbimycine a, compositions les contenant et utilisation
HK1254636A1 (zh) 作为可溶性鸟苷酸环化酶激活剂的茚满衍生物及其用途
MX2010007929A (es) Imidazolinilmetil aril sulfonamidas novedosas.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08805600

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08805600

Country of ref document: EP

Kind code of ref document: A2